Early Detection of Ovarian Cancer by Molecular Targeted Ultrasound Imaging Together with Serum Markers of Tumor-Associated Nuclear Change and Angiogenesis

2013 ◽  
Author(s):  
Animesh Barua
Keyword(s):  
Ovarian Cancer ◽  
Early Detection ◽  
Ultrasound Imaging ◽  
Serum Markers ◽  
Nuclear Change ◽  
Targeted Ultrasound

Enhancement of Ovarian Tumor Detection by DR6-Targeted Ultrasound Imaging Agents in Laying Hen Model of Spontaneous Ovarian Cancer

2016 ◽  
Vol 26 (8) ◽  
pp. 1375-1385 ◽  
Author(s):  
Animesh Barua ◽  
Seby L. Edassery ◽  
Sa’Rah McNeal ◽  
Janice M. Bahr ◽  
Pincas Bitterman ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Early Detection ◽  
Ultrasound Imaging ◽  
Signal Intensity ◽  
Laying Hen ◽  
Imaging Agents ◽  
Targeted Imaging ◽  
Malignant Cells ◽  
Targeted Ultrasound ◽  
Signal Intensities

ObjectiveThe lack of an effective early detection test leads to high case to death ratio of women with ovarian cancer (OVCA). To improve early detection, tumor-associated imaging targets need to be established and imaging agents to image these targets need to be developed. Targeted imaging agents offer potential for improvement of signal intensities from their targets. Expression of death receptor 6 (DR6) by ovarian malignant cells and tumor-associated microvessels increases during OVCA development and represents a novel target for ultrasound imaging. The goal of this study was to examine the feasibility of newly developed DR6-targeted ultrasound imaging agents in enhancing early detection of ovarian tumors in laying hen model of spontaneous OVCA.Materials and MethodsThe study was conducted in an exploratory cross-sectional design using 4-year-old laying hens (n = 130). DR6-targeted imaging agents were developed by conjugating microbubbles with rabbit anti-chicken DR6 antibodies. Changes in signal intensity of ultrasound imaging were determined before and after injection of targeted imaging agents in hens with or without spontaneous OVCA. Following targeted imaging, normal or tumor ovaries were processed for histopathological and immunohistochemical studies.ResultsDR6-targeted imaging agents bound with their targets expressed by malignant cells and tumor-associated microvessels in the ovary. Compared with pretargeted imaging, targeted imaging is enhanced by approximately 40% ultrasound echo signal intensity (P< 0.001) from early- and late-stage OVCA. Differences in signal enhancement were not observed among different histological subtypes of OVCA at early or late stages. Higher imaging signal intensities were associated with enhancement in DR6 expression by ovarian malignant cells and increase in the frequency of DR6-expressing microvessels during OVCA development.ConclusionsThe results of this study suggest that DR6-targeted imaging agents enhance the visualization of ovarian tumors and tumor-associated microvessels in hens with early-stage OVCA and will form a foundation for clinical studies.

scholarly journals Development of a Targeted Ultrasound Microbubble for Early Detection of Ovarian Cancer

2020 ◽  
Vol 34 (S1) ◽  
pp. 1-1
Author(s):  
Meghan M. Flannery ◽  
Kalpana Deepa Priya Dorayappan ◽  
Corinne A. Calo ◽  
Eileen L. Kalmar ◽  
Michael F. Tweedle ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Early Detection ◽  
Targeted Ultrasound

Evaluation of the novel serum markers B7-H4, Spondin 2, and DcR3 for diagnosis and early detection of ovarian cancer

2007 ◽  
Vol 106 (1) ◽  
pp. 112-118 ◽  
Author(s):  
Iris Simon ◽  
Yan Liu ◽  
Kirstin L. Krall ◽  
Nicole Urban ◽  
Robert L. Wolfert ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Early Detection ◽  
Serum Markers ◽  
The Novel

scholarly journals Early Detection of Ovarian Cancer

2007 ◽  
Vol 23 (5-6) ◽  
pp. 397-410 ◽  
Author(s):  
Donna Badgwell ◽  
Robert C. Bast Jr.
Keyword(s):  
Ovarian Cancer ◽  
Early Detection ◽  
Cost Effective ◽  
Serum Markers ◽  
Stage I ◽  
Expression Cloning ◽  
Great Promise ◽  
Early Stage Disease ◽  
Effective Screening ◽  
Stage Disease

Despite advances in therapy, ovarian cancer remains the most deadly of the gynecological cancers. Less than 30% of women with advanced stage disease survive long-term. When diagnosed in stage I, up to 90% of patients can be cured with conventional surgery and chemotherapy. At present, only 25% of ovarian cancers are detected in stage I due, in part, to the absence of specific symptoms and to lack of an effective screening strategy. Early detection of ovarian cancer might significantly improve the overall survival rate of women with ovarian cancer if 1) most cancers are clonal and unifocal, arising in the ovary rather than in the peritoneum, 2) metastatic disease results from progression of clinically detectable stage I lesions, and 3) cancers remain localized for a sufficient interval to permit cost-effective screening. Given the prevalence of ovarian cancer, strategies for early detection must have high sensitivity for early stage disease (> 75%), but must have extremely high specificity (99.6%) to attain a positive predictive value of at least 10%. Transvaginal sonography (TVS), serum markers and a combination of the two modalities have been evaluated for early detection of ovarian cancer. Among the serum markers, CA125 has received the most attention, but lacks the sensitivity or specificity to function alone as a screening test. Greater specificity can be achieved by combining CA125 and TVS and/or by monitoring CA125 over time. Two stage screening strategies promise to be cost effective, where abnormal serum assays prompt TVS to detect lesions that require laparotomy. Accrual has been completed for a 200,000 woman trial in the United Kingdom that will test the ability of a rising CA125 to trigger TVS and subsequent exploratory surgery. Given the heterogeneity of ovarian cancer, it is unlikely that any single marker will be sufficiently sensitive to provide an effective initial screen. Sensitivity of serum assays might be enhanced by utilizing a panel of biomarkers. Candidate biomarkers have been discovered through empirical development of monoclonal antibodies, studies of gene expression, cloning of gene families and proteomic techniques. The development of technologies that measure multiple serum markers simultaneously, linked to the creation of statistical methods that enhance sensitivity without sacrificing specificity hold great promise.

VEGFR2-Targeted Ultrasound Imaging Agent Enhances the Detection of Ovarian Tumors at Early Stage in Laying Hens, a Preclinical Model of Spontaneous Ovarian Cancer

2014 ◽  
Vol 37 (3) ◽  
pp. 224-237 ◽  
Author(s):  
Animesh Barua ◽  
Aparna Yellapa ◽  
Janice M. Bahr ◽  
Sergio A. Machado ◽  
Pincas Bitterman ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Ultrasound Imaging ◽  
Laying Hens ◽  
Early Stage ◽  
Ovarian Tumors ◽  
Imaging Agent ◽  
Preclinical Model ◽  
Targeted Ultrasound
Sign in / Sign up

Export Citation Format

Share Document